CN100562570C - 修饰的重组痘苗病毒及其它微生物,及其应用 - Google Patents

修饰的重组痘苗病毒及其它微生物,及其应用 Download PDF

Info

Publication number
CN100562570C
CN100562570C CNB2004800236108A CN200480023610A CN100562570C CN 100562570 C CN100562570 C CN 100562570C CN B2004800236108 A CNB2004800236108 A CN B2004800236108A CN 200480023610 A CN200480023610 A CN 200480023610A CN 100562570 C CN100562570 C CN 100562570C
Authority
CN
China
Prior art keywords
gene
cells
vaccinia virus
microorganisms
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004800236108A
Other languages
English (en)
Chinese (zh)
Other versions
CN1839201A (zh
Inventor
阿拉达尔·A.·绍洛伊
塔季扬娜·季米尔亚索娃
余勇
张谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genelux Corp
Original Assignee
Genelux Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03013826A external-priority patent/EP1489164A1/en
Priority claimed from EP03018478A external-priority patent/EP1512746B1/en
Priority claimed from EP03024283A external-priority patent/EP1526185B1/en
Application filed by Genelux Corp filed Critical Genelux Corp
Publication of CN1839201A publication Critical patent/CN1839201A/zh
Application granted granted Critical
Publication of CN100562570C publication Critical patent/CN100562570C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2004800236108A 2003-06-18 2004-06-18 修饰的重组痘苗病毒及其它微生物,及其应用 Expired - Lifetime CN100562570C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP03013826.7 2003-06-18
EP03013826A EP1489164A1 (en) 2003-06-18 2003-06-18 Recombinant vaccinia viruses with modified F3 genes, uses thereof
EP03018478.2 2003-08-14
EP03018478A EP1512746B1 (en) 2003-08-14 2003-08-14 Method for the production of a polypeptide, RNA or other compound in tumor tissue
EP03024283.8 2003-10-22
EP03024283A EP1526185B1 (en) 2003-10-22 2003-10-22 Use of a microorganism or cell to induce autoimmunization of an organism against a tumor

Publications (2)

Publication Number Publication Date
CN1839201A CN1839201A (zh) 2006-09-27
CN100562570C true CN100562570C (zh) 2009-11-25

Family

ID=34119412

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800236108A Expired - Lifetime CN100562570C (zh) 2003-06-18 2004-06-18 修饰的重组痘苗病毒及其它微生物,及其应用

Country Status (13)

Country Link
US (11) US7588767B2 (enExample)
EP (2) EP2028270B9 (enExample)
JP (4) JP3934673B1 (enExample)
CN (1) CN100562570C (enExample)
AT (2) ATE545699T1 (enExample)
AU (2) AU2004289953B2 (enExample)
BR (1) BRPI0411526A (enExample)
CA (1) CA2527225C (enExample)
DE (1) DE602004018927D1 (enExample)
MX (1) MXPA05013879A (enExample)
RU (1) RU2376371C2 (enExample)
SG (1) SG179291A1 (enExample)
WO (1) WO2005047458A2 (enExample)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0109515D0 (en) * 2001-04-17 2001-06-06 Neg Micon As A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
CN1754002B (zh) 2002-08-12 2010-09-08 杰能斯有限公司 涉及痘病毒和癌的组合物及制备方法
BRPI0411526A (pt) * 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
US8221739B2 (en) 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
AU2006287441B2 (en) * 2005-09-07 2012-09-06 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
CN101296702B (zh) 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
US20070077231A1 (en) * 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
US20070098828A1 (en) * 2005-11-01 2007-05-03 Gonzalez-Villasenor Lucia I Methods and compositions for the prevention and regression of neovascularization
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
WO2007075879A2 (en) * 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
ES2536423T3 (es) 2006-01-05 2015-05-25 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cáncer de próstata
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
ES2442890T3 (es) 2006-07-13 2014-02-14 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon
ES2374446T3 (es) 2006-09-19 2012-02-16 The Ohio State University Research Foundation Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181.
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
EP2087135B8 (en) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
CN105256004A (zh) 2007-01-31 2016-01-20 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
KR100858913B1 (ko) * 2007-03-09 2008-09-17 한국과학기술원 부위특이적 변이에 의해 제조된 고수율의 ｌ－쓰레오닌생산균주 및 이를 이용한 ｌ－쓰레오닌의 제조방법
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008141226A2 (en) * 2007-05-10 2008-11-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US8012738B2 (en) * 2007-05-14 2011-09-06 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
MX2009012924A (es) * 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CA2693623A1 (en) * 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
JP2010535782A (ja) 2007-07-31 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法
ES2562077T3 (es) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
US7807180B2 (en) * 2007-08-21 2010-10-05 University Of Massachusetts Poxvirus methods and compositions
EP2183593B1 (en) 2007-08-22 2016-01-13 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009046449A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHOD FOR IDENTIFYING FHIT INTERACTION AND USE
ES2567564T3 (es) * 2007-11-19 2016-04-25 Transgene Sa Vectores oncolíticos de poxvirus
NZ584201A (en) * 2007-11-19 2012-06-29 Transgene Sa Poxviral oncolytic vectors comprising a defective f2l gene
WO2009126189A1 (en) * 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
EP2276774B1 (en) 2008-03-14 2016-08-17 Retrotope, Inc. Therapeutic substances that modulate genome methylation
WO2009114809A1 (en) * 2008-03-14 2009-09-17 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
US20110172107A1 (en) * 2008-04-30 2011-07-14 Fox Chase Cancer Center Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby
US8825503B2 (en) * 2008-05-15 2014-09-02 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
CA2729080C (en) * 2008-07-03 2018-09-11 Ricardo Rosenbusch Cattle vaccines
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
ES2585242T3 (es) * 2008-09-19 2016-10-04 Etat Francais Représenté Par Le Directeur Central Du Service De Santé Des Armées Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
HUE038708T2 (hu) 2009-09-14 2018-11-28 Sillajen Biotherapeutics Inc Onkolitikus vaccinia vírus kombinációs rákterápia
US8916533B2 (en) 2009-11-23 2014-12-23 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
WO2011150421A2 (en) * 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
RU2447150C1 (ru) * 2010-11-26 2012-04-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Средство для генной терапии злокачественных опухолей
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2683387A4 (en) 2011-03-07 2014-09-03 Univ Ohio State MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
CN102685768B (zh) 2011-03-08 2016-02-03 华为技术有限公司 心跳消息的处理方法、心跳周期的获取方法及接入网设备
CN114262690A (zh) * 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
CN102286415B (zh) * 2011-09-07 2014-03-05 天津工业生物技术研究所 琥珀酸高产菌株及其应用
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
PE20142362A1 (es) * 2011-11-18 2015-01-30 Alnylam Pharmaceuticals Inc Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
CA2859430A1 (en) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
US8828681B2 (en) 2012-01-13 2014-09-09 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US9023612B2 (en) 2012-01-13 2015-05-05 Bell Biosystems, Inc. Eukaryotic cells with artificial endosymbionts for multimodal detection
US10076579B2 (en) 2012-01-13 2018-09-18 Bell Biosystems, Inc. Host cells with artificial endosymbionts
US8956873B2 (en) 2012-01-13 2015-02-17 Bell Biosystems, Inc. Host cells with artificial endosymbionts
CA2866052A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US9861402B2 (en) * 2012-03-08 2018-01-09 Trimed, Incorporated System and method for treating a fractured bone
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
KR102086874B1 (ko) * 2012-04-11 2020-03-10 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2014145785A1 (en) 2013-03-15 2014-09-18 Bell Biosystems, Llc Host cells with artificial endosymbionts
CN103589656A (zh) * 2013-05-28 2014-02-19 湖北省农业科学院畜牧兽医研究所 猪传染性胸膜肺炎放线杆菌血清1型锌离子结合蛋白a缺失株及其构建方法和应用
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
GB201310917D0 (en) * 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy
CA2923177A1 (en) 2013-09-03 2015-03-12 Bell Biosystems, Inc. Host cell modification with artificial endosymbionts
US20150064760A1 (en) * 2013-09-05 2015-03-05 Braskem S.A. Modified microorganism and methods of using same for producing butadiene and 1-propanol and/or 1,2-propanediol
US10028649B2 (en) * 2013-12-02 2018-07-24 Welch Allyn, Inc. Digital colposcope system
CN104694541A (zh) * 2013-12-09 2015-06-10 江苏命码生物科技有限公司 禽流感病毒miRNA及其鉴定、检测和应用
CN106795550A (zh) * 2013-12-30 2017-05-31 促进军事医学的亨利·M·杰克逊基金会公司 与前列腺癌有关的基因组重排和使用所述基因组重排的方法
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN103743903A (zh) * 2014-01-08 2014-04-23 江苏省苏北人民医院 肝癌术后复发预测标志物Capn4检测方法及试剂盒
EP3825411A1 (en) 2014-06-18 2021-05-26 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
JP2017522022A (ja) * 2014-07-15 2017-08-10 ベル・バイオシステムズ，インコーポレーテッド マルチモーダル検出のための人工内部共生体を含む真核細胞
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105586319B (zh) * 2014-10-20 2021-01-08 中国疾病预防控制中心性病艾滋病预防控制中心 复制型痘苗病毒载体艾滋病疫苗
ES2841075T3 (es) 2014-10-24 2021-07-07 Calidi Biotherapeutics Inc Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
WO2016102569A1 (en) 2014-12-22 2016-06-30 Veterinærinstituttet Salmon gill poxvirus
KR101829845B1 (ko) * 2015-01-18 2018-02-19 엘지전자 주식회사 방송 신호 송신 장치, 방송 신호 수신 장치, 방송 신호 송신 방법, 및 방송 신호 수신 방법
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR101835180B1 (ko) 2015-03-18 2018-03-06 아주대학교산학협력단 재조합 BTG2(B cell translocation gene 2) 단백질 및 이의 생산방법
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
JP6788663B2 (ja) 2015-08-11 2020-11-25 カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 癌処置のための天然痘ワクチン
WO2017074517A1 (en) * 2015-10-30 2017-05-04 Seracare Life Sciences, Inc. Adenovirus control virus
WO2017106790A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CN106978397A (zh) * 2016-01-18 2017-07-25 上海宇研生物技术有限公司 一种人dc-cik免疫活性细胞及其制备方法
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
AU2017241684B2 (en) 2016-03-28 2020-05-21 Suzhou Prajna Biotech Co., Ltd. Anti-cancer oncolytic virus combination therapies and elite responder selection platforms
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
EP3489354B1 (en) 2016-07-21 2024-03-27 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
AU2017311380A1 (en) * 2016-08-09 2019-03-28 City Of Hope Chimeric poxvirus compositions and uses thereof
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
US20190330613A1 (en) * 2016-11-24 2019-10-31 Cathay R&D Center Co., Ltd. Control of protein to protein interactions of acid decarboxylase
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3550976A4 (en) 2016-12-07 2020-06-10 MD Biosciences, Inc. METHOD FOR SYNERGISTIC TREATMENT OF CANCER
RU2658606C1 (ru) * 2017-01-26 2018-06-21 Рашит Накипович Кадыров Штамм streptococcus pyogenes n b-7612, продуцент комплекса биологически активных соединений, обладающих иммуностимулирующими свойствами
CA3052473A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
US20190134105A1 (en) * 2017-11-09 2019-05-09 Richard Postrel Method for Precise Identification, Targeting and Delivery of Directed Therapies with the Use of Bacteria for the Destruction of Cancerous Cells
IL319966A (en) 2017-03-16 2025-05-01 Alpine Immune Sciences Inc CD80 Variant Immune Modulator Proteins and Uses Thereof
CA3053812A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US12275994B2 (en) 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
CN107164338A (zh) * 2017-06-27 2017-09-15 镇江市卫克生物科技有限公司 一种重组溶瘤病毒及其应用
US10851350B1 (en) 2017-06-27 2020-12-01 Genelux Corporation Bioreactor production of virus from adherent cells
CN117106037B (zh) * 2017-06-30 2025-07-25 弗拉芒区生物技术研究所 新颖蛋白孔
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
TW202500579A (zh) 2017-10-18 2025-01-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
EP3728301A4 (en) 2017-12-20 2021-10-06 Radimmune Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST CENTRIN-1, THEIR MANUFACTURING PROCESSES AND THEIR USES
CN111511397A (zh) 2017-12-22 2020-08-07 科达金尼克斯有限公司 具有密码子对去优化区域的重组病毒及其用于治疗癌症的用途
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN108489941B (zh) * 2018-01-31 2021-07-27 吉林大学 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用
DK3762499T5 (da) * 2018-03-06 2024-08-26 Danisco Us Inc Reduktion i acetatproduktion ved hjælp af gær, der overudtrykker pab1
CN112040977A (zh) 2018-03-08 2020-12-04 科达金尼克斯有限公司 减毒黄病毒
CN110386985B (zh) * 2018-04-19 2022-09-20 四川大学华西医院 一种肿瘤靶向性促凋亡融合蛋白及其用途
CN112534066B (zh) 2018-05-17 2025-01-24 二牛药物疗法公司 诊断血液测试
ES2966045T3 (es) 2018-06-04 2024-04-18 Calidi Biotherapeutics Inc Vehículos basados en células para la potenciación de la terapia viral
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
CN109172613B (zh) * 2018-08-14 2022-04-22 景岳生物科技(中国)有限公司 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CA3113965A1 (en) 2018-09-26 2020-04-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102806666B1 (ko) * 2018-10-30 2025-05-12 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 샘플 품질 평가 방법
CA3116192C (en) * 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
CN109546191B (zh) * 2018-11-07 2021-06-18 大连理工大学 一种混合基质型阴离子膜及其制备方法
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
EP3891123A4 (en) 2018-12-03 2022-12-14 Board of Regents, The University of Texas System ANALOGS OF OLIGO-BENZAMIDE AND THEIR USE IN THE TREATMENT OF CANCER
KR20210113632A (ko) * 2019-01-07 2021-09-16 칼리버 임뮤노쎄라퓨틱스, 인크. 암을 치료하는 방법
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
JP2022520220A (ja) * 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
WO2020172461A1 (en) * 2019-02-22 2020-08-27 Arizona Board Of Regents On Behalf Of Arizona State University Using tumor-navigating salmonella to modulate tumor metabolism
MX2021010273A (es) 2019-02-27 2021-09-23 Actym Therapeutics Inc Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN109810991B (zh) * 2019-03-02 2021-11-12 昆明理工大学 二氢蝶酸合酶基因folP的用途
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN113874029B (zh) * 2019-04-01 2025-02-11 汉阳大学校产学协力团 基于cp2c靶向肽的抗癌剂
CN109957551B (zh) * 2019-04-03 2021-03-23 浙江省医学科学院 表达人β-防御素2的重组痘苗病毒及其应用
JP2022531976A (ja) * 2019-05-15 2022-07-12 コーダ－ジェニックス・インコーポレイテッド 弱毒化黄熱ウイルス及びがんの処置のためのその使用
JP2022534783A (ja) * 2019-06-03 2022-08-03 イミュノルクス インターナショナル コーポレーション 疾患を処置するための天然痘ワクチン及び幹細胞
BR112022001881A2 (pt) 2019-08-29 2022-06-21 Astellas Pharma Inc Vírus vaccinia oncolítico geneticamente manipulado e métodos de usos do mesmo
CN110713962B (zh) * 2019-09-06 2022-06-21 南京农业大学 一株高产丙二酰辅酶a的基因工程菌及其构建方法和应用
CN110585427B (zh) * 2019-09-06 2023-06-06 刘慧宁 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用
US11271912B2 (en) * 2019-09-27 2022-03-08 Envistacom, Llc Anonymous communication over virtual, modular, and distributed satellite communications network
CN110551672B (zh) * 2019-09-30 2023-05-23 中国科学院成都生物研究所 高产反式-4-羟基-l-脯氨酸的大肠杆菌菌株及其构建方法
CN110564867B (zh) * 2019-10-10 2022-06-24 扬州大学 一种秦川牛cfl1基因的snp分子标记及其检测方法
CN110747174A (zh) * 2019-10-30 2020-02-04 青岛宁逸生物科技有限公司 一种用于肿瘤治疗的重组病毒
KR20220113467A (ko) 2019-12-12 2022-08-12 이그나이트 이뮤노테라피, 인크. 변이체 종양용해성 백시니아 바이러스 및 그의 사용 방법
CN111254219B (zh) * 2019-12-27 2023-08-04 上海华盈生物医药科技有限公司 一种用于进行病毒包装效率检测的方法
CN111019877B (zh) * 2019-12-31 2022-04-19 浙江工业大学 一种产l-半胱氨酸的基因工程菌、构建方法及应用
MX2022008547A (es) 2020-01-09 2022-08-10 Pfizer Virus de vacuna recombinante.
GB2609103A (en) * 2020-02-25 2023-01-25 Quell Therapeutics Ltd Chimeric receptors for use in engineered cells
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111875699B (zh) * 2020-07-03 2022-07-05 江南大学 一种提高枯草芽孢杆菌卵清蛋白表达量的方法
WO2022013696A2 (en) 2020-07-14 2022-01-20 Pfizer Inc. Recombinant vaccinia virus
CN111705144B (zh) * 2020-07-17 2022-11-18 扬州大学 一个与猪背膘厚关联的znf2基因内sine转座子多态分子标记及其检测方法
CN111913584B (zh) * 2020-08-19 2022-04-01 福州大学 一种基于手势识别的鼠标光标控制方法及系统
CN112011555A (zh) * 2020-09-09 2020-12-01 西南大学 一种调控沙门氏菌自裂解的重组基因、重组质粒及其应用
JP2023544184A (ja) 2020-10-02 2023-10-20 ジェネラックス・コーポレイション 接着細胞からのウイルスのバイオリアクター生成
CN112149041B (zh) * 2020-10-20 2022-12-16 贵州电网有限责任公司 一种基于psd-bpa数据及图形化交互技术的故障分析方法
EP4247410A4 (en) 2020-11-19 2025-05-07 KaliVir Immunotherapeutics, Inc. ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
CN114584999B (zh) * 2020-11-30 2023-08-15 中国移动通信集团山西有限公司 一种监测系统、方法、设备及计算机存储介质
CN113322275A (zh) * 2021-03-24 2021-08-31 中国人民解放军空军军医大学 一种巨噬细胞的CRISPR/Cas9表观编辑系统、方法、编辑后的巨噬细胞和应用
CN115232871A (zh) * 2021-04-02 2022-10-25 武汉儿童医院 Spi1基因表达水平检测物在产后抑郁症检测中的应用及检测系统
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
CN113363963B (zh) * 2021-05-20 2022-05-20 南昌大学 一种改进麻雀搜索算法优化三相sapf直流侧控制方法
CN113249286B (zh) * 2021-05-25 2023-12-08 洛阳华荣生物技术有限公司 一种构建l-肌氨酸生产菌的方法
CN113322213B (zh) * 2021-07-09 2022-05-13 吉林大学 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用
CN114395574B (zh) * 2022-01-18 2023-08-11 长沙爱科博生物科技有限公司 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用
CN115304679B (zh) * 2022-01-21 2024-07-16 郑州大学第一附属医院 一种促进t细胞分化的限制型car及其应用
US20230233299A1 (en) * 2022-01-27 2023-07-27 EdgeEndo, LLC Dental, endodontic, and periodontic treatment methods and systems
CN114540521B (zh) * 2022-03-23 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有降糖降脂功效的植物乳杆菌84-3特异性分子靶标及其检测方法
CN114774468B (zh) * 2022-04-20 2022-12-20 温氏食品集团股份有限公司 一种等位基因分子标记及抗蓝耳病猪群体组建方法
CN115011601B (zh) * 2022-06-27 2023-07-21 山东大学齐鲁医院 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用
CA3260631A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic and recombinant vaccine viruses and their methods of use
CN117625547B (zh) * 2022-08-25 2024-06-28 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用
CN115838803A (zh) * 2022-09-29 2023-03-24 上海中医药大学附属龙华医院 结直肠癌患者预后及对免疫检查点抑制剂应答效率的生物标志物及其应用
CN117757704B (zh) * 2022-12-19 2024-08-27 元素驱动(杭州)生物科技有限公司 一种提高支链氨基酸（bcaa）产量的方法及菌株构建
CN116309507B (zh) * 2023-03-29 2025-11-18 西南大学 注意力机制下对ctp进行特征融合的ais病灶预测方法
CN116622577B (zh) * 2023-05-26 2023-10-27 山东奈思健康科技有限责任公司 一种促进col1a2和col3a1表达提高胶原蛋白合成的后生元及其制备方法
CN117603892B (zh) * 2023-09-08 2025-12-05 吉林大学 oahs基因缺失株及其在预防猪链球菌2型感染中的应用
CN117269496B (zh) * 2023-09-27 2024-08-13 山东大学齐鲁医院 一种评估胆管癌预后的生物标志物及其应用
CN117589991B (zh) * 2024-01-18 2024-03-29 天津云检医学检验所有限公司 一种用于乳腺癌患者her2表达状态鉴定的生物标志物、模型、试剂盒及用途
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
CN119876203B (zh) * 2025-03-25 2025-08-12 宁波大学 过表达细菌素合成调控基因及其重组植物乳植杆菌的构建方法和应用
CN119931940B (zh) * 2025-04-08 2025-07-29 上海交通大学医学院附属仁济医院 增强i型经典树突状细胞分化效率和存活时长的方法
CN120060476A (zh) * 2025-04-25 2025-05-30 湖南省人民医院(湖南师范大学附属第一医院) 一种前列腺癌奥拉帕利治疗耐药标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083527A (zh) * 1992-06-16 1994-03-09 联邦科学及工业研究组织 重组昆虫痘病毒
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US54865A (en) * 1866-05-22 Improvement in cow-milkers
US59400A (en) * 1866-11-06 Improvement
US8025A (en) * 1851-04-08 Apparatus eor boltiitg flouk
US165477A (en) * 1875-07-13 Improvement in smelting-furnaces
US76622A (en) * 1868-04-14 Bobeet john gaines
US160970A (en) * 1875-03-16 Improvement in key-rings
US69491A (en) * 1867-10-01 Newark
US86906A (en) * 1869-02-16 Improvement in velocipedes
US31681A (en) * 1861-03-12 Puhchifg-machine
US29023A (en) * 1860-07-03 Cornelius j
US165465A (en) * 1875-07-13 Improvement in paper-weights
US228330A (en) * 1880-06-01 Advertising checker-board
US143861A (en) * 1873-10-21 Improvement in picture-frames
US31628A (en) * 1861-03-05 Improvement in sewing-machines
US9015A (en) * 1852-06-15 Manufacture of granular fuel from brush-wood and twigs
US101480A (en) * 1870-04-05 Improvement in hand seed-planter
US83293A (en) * 1868-10-20 Improvement in button-hole cutters
US161788A (en) * 1875-04-06 Improvement in bird-cages
US160410A (en) * 1875-03-02 Improvement in carbureters or hydrocarbon-diffusers
US213741A (en) * 1879-04-01 Improvement in portable platforms for fire and other ladders
US228261A (en) * 1880-06-01 lewis
US213007A (en) * 1879-03-04 Improvement in safety-pins
US44384A (en) * 1864-09-27 Improved carpet-fastening
US33617A (en) * 1861-10-29 Improvement in grain-separators
US31643A (en) * 1861-03-05 Bons l
JPS5535004Y2 (enExample) 1975-07-28 1980-08-19
JPS542336A (en) * 1977-06-06 1979-01-09 Meiji Seika Kaisha Ltd Preventive and remedy for viral diseases
JPS5535004A (en) 1978-09-02 1980-03-11 Wakunaga Yakuhin Kk Cell-immunity activator and its preparation
EP0037441B1 (en) 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
US4442203A (en) 1981-06-30 1984-04-10 Massachusetts Institute Of Technology Gene amplification assay for detecting tumor promoters
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4778759A (en) 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
EP0274527B1 (en) 1986-07-22 1994-05-04 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5866136A (en) 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
ZA891067B (en) 1988-02-12 1990-04-25 Commw Scient Ind Res Org Pox virus vectors
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
WO1990013658A1 (en) 1989-04-28 1990-11-15 The University Of Alberta Plant hormone regulated expression of genetically engineered gene products in plant cells
WO1991007989A1 (en) 1989-11-28 1991-06-13 Universite Laval A method of inactivating human immunodeficiency virus
CA2085127C (en) 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
CA2105277C (en) 1991-03-07 2006-12-12 William I. Cox Genetically engineered vaccine strain
US5863542A (en) 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5212082A (en) 1991-03-13 1993-05-18 New York University Genetically modified tyrosine hydroxylase and uses thereof
US5800829A (en) 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5718902A (en) 1991-06-17 1998-02-17 The Regents Of The University Of California Double recombinant vaccinia virus vaccines
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE69330640T2 (de) 1992-05-29 2002-07-04 Vivorx, Inc. Mikroverkapselung von zellen
WO1994010302A1 (de) 1992-10-29 1994-05-11 Boehringer Mannheim Gmbh Amplifizierbarer vektor gegen hiv replikation
DE9302762U1 (de) * 1993-02-25 1993-04-15 Kelm, Eckehart, 8031 Gilching Verstelleinrichtung für ein Hebeschiebedach
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
FR2710536B1 (fr) 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
CA2190290C (en) 1994-05-13 2011-07-05 Michael J. Mastrangelo A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
JPH07313187A (ja) 1994-05-24 1995-12-05 Sagami Chem Res Center 抗体作製法
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5776747A (en) 1994-07-20 1998-07-07 Cytotherapeutics, Inc. Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer
US5853385A (en) 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
DK0784483T3 (da) 1994-10-03 2001-03-26 Us Gov Health & Human Serv Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul
EP0789774A2 (en) 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US5693533A (en) 1994-12-07 1997-12-02 The Goodwin Institue For Cancer Research Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing
US6503703B1 (en) * 1995-05-19 2003-01-07 Mount Sinai School Of Medicine Of New York University Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5842431A (en) 1997-02-19 1998-12-01 Wu; Chong-Ming Rotating shuttle and presser plate arrangement
US6251384B1 (en) 1997-04-28 2001-06-26 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
US6232523B1 (en) 1997-04-28 2001-05-15 Anticancer, Inc. Metastasis models using green fluorescent protein (GFP) as a marker
DE69839603D1 (de) 1997-04-28 2008-07-24 Anticancer Inc Zierenden proteins
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6265557B1 (en) 1997-05-09 2001-07-24 Loma Linda University Medical Center ABO histo-blood group O alleles of the baboon
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6106826A (en) 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
US6065557A (en) * 1998-04-01 2000-05-23 Von Keyserling; Peter H. Power assist assembly for wheeled vehicles
US6713293B1 (en) 1999-02-08 2004-03-30 Friedrich Grummt Encapsulated cells containing an amplified expression vector as a drug delivery device
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6511967B1 (en) 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
AU5446700A (en) 1999-05-28 2000-12-18 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
AU6909700A (en) 1999-08-16 2001-03-13 Uab Research Foundation Gene transfer imaging and uses thereof
AU7572900A (en) 1999-08-26 2001-03-19 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
AU779263B2 (en) 1999-09-08 2005-01-13 Xenogen Corporation Luciferase expression cassettes and methods of use
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
WO2001025399A2 (en) 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
WO2001025397A2 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
AU2462101A (en) 1999-12-29 2001-07-09 Vanderbilt University Genetic mutation underlying orthostatic intolerance and diagnostic and therapeutic methods relating thereto
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
DE60109581T2 (de) 2000-01-26 2006-01-19 Loma Linda University, Loma Linda Verfahren für die evaluierung von implantierbaren materialien
US6448073B1 (en) * 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
CA2403090C (en) 2000-03-17 2014-06-10 Anticancer, Inc. Whole-body optical imaging of gene expression and uses thereof
DE10013511A1 (de) * 2000-03-20 2001-10-11 Brand Gmbh & Co Kg Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür
TW541342B (en) 2000-04-04 2003-07-11 Nippon Steel Corp Hot rolled h-shap steel having an uniform microstruture and mechanical properties
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
US20020054865A1 (en) 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
KR20030085131A (ko) * 2001-02-22 2003-11-03 나노머슬, 인크. 온도제어를 개선한 형상기억합금 액츄에이터
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
CN1738649A (zh) 2001-07-09 2006-02-22 抗癌公司 用荧光蛋白作为标记物使感染成像
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
EP1281772A1 (en) 2001-07-31 2003-02-05 Aladar A. Szalay Light-emitting microorganisms and cells for tumour diagnosis/therapy
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US6840758B2 (en) * 2001-10-26 2005-01-11 Mold-Masters Limited Valve bushing assembly
AU2002350235A1 (en) 2001-11-21 2003-06-10 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
IL158297A0 (en) 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
CN1623001A (zh) 2001-12-31 2005-06-01 抗癌公司 监视细菌肿瘤治疗的系统
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
EP1487463A2 (en) 2002-03-02 2004-12-22 Board Of Regents The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
AU2003219057A1 (en) 2002-03-15 2003-09-29 Baxter Healthcare S.A. Recombinant drug-sensitive vaccinia virus as smallpox vaccine
US20030213007A1 (en) 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
EP1513924A4 (en) 2002-05-29 2008-05-21 Univ California ATTENUATED LISTERIA SPP. AND METHOD OF USE THEREOF
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
US20030228261A1 (en) 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
WO2004000236A2 (en) 2002-06-25 2003-12-31 The Ohio State University Research Foundation Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
US7355162B2 (en) * 2002-07-02 2008-04-08 Optitune Plc Optical wavelength measuring device using guiding body and diffractive structure
CN1754002B (zh) 2002-08-12 2010-09-08 杰能斯有限公司 涉及痘病毒和癌的组合物及制备方法
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
US7318917B2 (en) 2002-09-06 2008-01-15 Vanderbilt University Rapid assays for neurotransmitter transporters
US20080159957A1 (en) 2002-10-01 2008-07-03 W Michael Kavanaugh Anti-Cancer and Anti-Infectious Disease Compositions and Methods for Using Same
AU2003290819A1 (en) 2002-11-12 2004-06-03 Anticancer, Inc. Fluorescence guided cell capture
WO2004098534A2 (en) 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
AU2004218407A1 (en) 2003-03-03 2004-09-16 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
US8452294B2 (en) 2003-04-23 2013-05-28 Qualcomm Incorporated In-band ate indicator methods and apparatus
EP1526185B1 (en) 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
EP1489164A1 (en) 2003-06-18 2004-12-22 Genelux GmbH Recombinant vaccinia viruses with modified F3 genes, uses thereof
BRPI0411526A (pt) 2003-06-18 2006-08-01 Genelux Corp vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
EP1512746B1 (en) 2003-08-14 2009-10-07 Genelux Corporation Method for the production of a polypeptide, RNA or other compound in tumor tissue
WO2005057488A2 (en) 2003-12-03 2005-06-23 Anticancer, Inc. Modular system for multi-color, whole body fluorescence imaging
WO2005072622A1 (en) 2004-01-26 2005-08-11 Anticancer, Inc. Whole body imaging using portable observation systems
WO2005094878A1 (ja) 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
US20060063993A1 (en) * 2004-08-09 2006-03-23 Dejin Yu Method and apparatus for non-invasive measurement of blood analytes
WO2006050274A2 (en) 2004-11-02 2006-05-11 Uab Research Foundation Methods and compositions for cytokine expression and treatment of tumors
US20060193832A1 (en) 2005-02-04 2006-08-31 University Of Iowa Research Foundation Use of the sodium iodine symporter to effect uptake of iodine
JP2006260179A (ja) * 2005-03-17 2006-09-28 Matsushita Electric Ind Co Ltd トラックボール装置
EP1924604B1 (en) 2005-08-17 2011-11-30 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Human monoclonal antibodies that specifically bind igf-ii
WO2007075879A2 (en) 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
ES2299362B1 (es) 2006-07-11 2009-04-01 Bestile, S.L. Baldosa para revestimiento y pavimentacion.
WO2008007377A2 (en) 2006-07-12 2008-01-17 Niti Surgical Solutions Ltd. Compression assemblies and applicators for use therewith
DE102006034854A1 (de) 2006-07-25 2008-01-31 Ovd Kinegram Ag Verfahren zur Erzeugen einer Lasermarkierung in einem Sicherheitsdokument sowie derartiges Sicherheitsdokument
US7947255B2 (en) 2006-08-09 2011-05-24 Vanderbilt University Fluorescent substrates for neurotransmitter transporters
US7569396B1 (en) * 2006-09-08 2009-08-04 Purplecow Llc Caffeine detection using internally referenced competitive assays
WO2008043851A1 (en) 2006-10-13 2008-04-17 N.V. Organon A non-homogeneous quencher free assay method for the noradrenaline transporter
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
CA2693623A1 (en) 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
WO2009126189A1 (en) * 2008-01-11 2009-10-15 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) * 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140086976A1 (en) * 2012-08-20 2014-03-27 Aladar A. Szalay Compositions containing protein polymers and vaccinia virus, and methods of use thereof
US20140140959A1 (en) * 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20140271549A1 (en) 2013-03-15 2014-09-18 Aladar A. Szalay Use of Antibiotics to Enhance Treatment With Therapeutic Viruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083527A (zh) * 1992-06-16 1994-03-09 联邦科学及工业研究组织 重组昆虫痘病毒
US6491905B1 (en) * 1993-09-14 2002-12-10 The Uab Research Foundation Recombinant bacterial cells for delivery of PNP to tumor cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HA基因侧翼重组痘苗病毒的生物学特性研究. 毛春生等.河南农业大学学报，第31卷第4期. 1997 *
NYVAC: A HIGHLY ATTENUATED STRAIN OF VACCINIAVIRUS. JAMES TARTAGLIA, ET AL.VIROLOGY,Vol.188 No.1. 1992 *
痘苗病毒载体与肿瘤基因治疗. 李忠义，万淘.微生物学杂志，第22卷第3期. 2002 *

Also Published As

Publication number Publication date
MXPA05013879A (es) 2006-06-27
DE602004018927D1 (de) 2009-02-26
US20100008946A1 (en) 2010-01-14
US20070025981A1 (en) 2007-02-01
RU2006100679A (ru) 2007-07-27
US8784836B2 (en) 2014-07-22
JP2007524385A (ja) 2007-08-30
US7588767B2 (en) 2009-09-15
EP1644492B1 (en) 2009-01-07
US8021662B2 (en) 2011-09-20
AU2004289953A1 (en) 2005-05-26
US20170095552A1 (en) 2017-04-06
US10463730B2 (en) 2019-11-05
AU2004289953B2 (en) 2008-09-25
US9492534B2 (en) 2016-11-15
US20140294891A1 (en) 2014-10-02
US7662398B2 (en) 2010-02-16
EP2028270B9 (en) 2012-04-25
US8221769B2 (en) 2012-07-17
EP2028270A3 (en) 2009-05-20
CA2527225A1 (en) 2005-05-26
ATE545699T1 (de) 2012-03-15
JP4961190B2 (ja) 2012-06-27
HK1084691A1 (en) 2006-08-04
JP5342932B2 (ja) 2013-11-13
US20120276010A1 (en) 2012-11-01
US20070212727A1 (en) 2007-09-13
ATE420160T1 (de) 2009-01-15
US20060051370A1 (en) 2006-03-09
JP2007020586A (ja) 2007-02-01
CA2527225C (en) 2010-05-11
US7588771B2 (en) 2009-09-15
SG179291A1 (en) 2012-04-27
BRPI0411526A (pt) 2006-08-01
US20070202572A1 (en) 2007-08-30
EP2028270A2 (en) 2009-02-25
HK1126818A1 (en) 2009-09-11
EP1644492A2 (en) 2006-04-12
US7754221B2 (en) 2010-07-13
AU2008264201A1 (en) 2009-01-29
JP4294711B2 (ja) 2009-07-15
WO2005047458A2 (en) 2005-05-26
US20050031643A1 (en) 2005-02-10
US8323959B2 (en) 2012-12-04
US20110300176A1 (en) 2011-12-08
EP2028270B1 (en) 2012-02-15
WO2005047458A3 (en) 2005-09-15
CN1839201A (zh) 2006-09-27
JP2008161196A (ja) 2008-07-17
JP2009201515A (ja) 2009-09-10
JP3934673B1 (ja) 2007-06-20
RU2376371C2 (ru) 2009-12-20
US20100062016A1 (en) 2010-03-11
AU2008264201B2 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
CN100562570C (zh) 修饰的重组痘苗病毒及其它微生物,及其应用
EP1180157B1 (en) A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
ES2733211T3 (es) Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
ZA200510193B (en) Modified recobinant vaccinia viruses and other micro-organisms, uses thereof
HK1126818B (en) Modified recombinant vaccinia viruses, uses thereof
HK1154628A (en) A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20091125